Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

About the molecule and how it works.

A specifically engineered anti-VEGF

A single-chain antibody fragment aims to facilitate deeper penetration of active molecules than larger molecules within tissue.1

Diagram with more information about the Beovu molecule

The molecule

Beovu has a high affinity to VEGF-A isoforms1 and can inhibit VEGF through prevention of the ligand-receptor interaction.

VEGF, vascular endothelial growth factor; VEGF-A, vascular endothelial growth factor A.

References

  1. Gaudreault J et al. Invest Ophthalmol Vis Sci. 2012; 53: 3025.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  3. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  4. Yannuzzi NA, Freund KB. Clin Ophthalmol. 2019; 13: 1323–1329.
Rate this content: 
Average: 2.3 (6 votes)
UK | May 2022 | 207568
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com